KRAS and neoplasm: Accordingly, ruxolitinib treatment markedly reduced tumor cell proliferation of human K‐RAS‐mutated A549 cells engrafted in immunodeficient NOD scid gamma mice and reduced a K‐RAS activation gene signature.